| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-16-1272 |
| P698 | PubMed publication ID | 27756788 |
| P50 | author | Michele Maio | Q37391116 |
| Caroline Robert | Q41784107 | ||
| Ignacio Melero, MD-PhD | Q60525568 | ||
| Mario Sznol | Q66809426 | ||
| Paolo Antonio Ascierto | Q89457677 | ||
| F Stephen Hodi | Q90321337 | ||
| Tara C Gangadhar | Q112885391 | ||
| P2093 | author name string | Vanna Chiarion-Sileni | |
| David McDermott | |||
| Omid Hamid | |||
| Walter J Urba | |||
| Neil H Segal | |||
| Maria Jure-Kunkel | |||
| Ronald Levy | |||
| Suba Krishnan | |||
| Holbrook Kohrt | |||
| Theodore F Logan | |||
| Henrik Schmidt | |||
| Satyendra Suryawanshi | |||
| Jaclyn Neely | |||
| P2860 | cites work | Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 |
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| monoclonal antibody | Q422248 | ||
| P304 | page(s) | 1929-1936 | |
| P577 | publication date | 2016-10-18 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody | |
| P478 | volume | 23 |
| Q92231834 | 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma |
| Q87981825 | 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses |
| Q59136671 | A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity |
| Q50187435 | Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. |
| Q47950137 | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression |
| Q64253759 | An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer |
| Q37222143 | Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity |
| Q64886488 | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. |
| Q56893015 | Bispecific antibodies in cancer immunotherapy |
| Q95840982 | Bispecific, T-Cell-Recruiting Antibodies in B-Cell Malignancies |
| Q59800859 | CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs |
| Q64898497 | CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages. |
| Q50125936 | Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies |
| Q92718021 | Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model |
| Q99637271 | Chronic activation of 4-1BB signaling induces granuloma development in tumor-draining lymph nodes that is detrimental to subsequent CD8+ T cell responses |
| Q47898168 | Combination therapy with the type II anti-CD20 antibody obinutuzumab. |
| Q90419584 | Current Perspectives in Cancer Immunotherapy |
| Q92385628 | Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells |
| Q78176712 | Delivery strategies of cancer immunotherapy: recent advances and future perspectives. |
| Q63246400 | Delivery technologies for cancer immunotherapy |
| Q50420978 | Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB). |
| Q90245083 | Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity |
| Q90686044 | Emerging strategies for combination checkpoint modulators in cancer immunotherapy |
| Q42363054 | Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. |
| Q94547635 | How to select IgG subclasses in developing anti-tumor therapeutic antibodies |
| Q64113842 | Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics |
| Q90503462 | Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum? |
| Q55503616 | Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. |
| Q54734909 | Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. |
| Q47281370 | Intratumoral immunotherapy: using the tumor as the remedy |
| Q96648027 | Mechanistic quantitative pharmacology strategies for the early clinical development of bispecific antibodies in oncology |
| Q60909519 | Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update |
| Q49539698 | Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets |
| Q92453577 | NK cells for cancer immunotherapy |
| Q52653710 | Next generation of immune checkpoint therapy in cancer: new developments and challenges. |
| Q90811943 | Nouvelles perspectives dans l’immunothérapie des cancers pédiatriques |
| Q64052040 | Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity |
| Q90529204 | Rational combination of cancer immunotherapy in melanoma |
| Q46113809 | Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation |
| Q92991917 | Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC |
| Q52597566 | S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. |
| Q58586476 | Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab |
| Q94526305 | Targeting T cell activation in immuno-oncology |
| Q56891562 | The promise and challenges of immune agonist antibody development in cancer |
| Q47325431 | Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications |
| Q92689796 | Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy |
| Q89690681 | Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma |
Search more.